AstraZeneca’s Imfinzi (durvalumab) + Imjudo (tremelimumab) Receive the US FDA’s Approval for Metastatic Non-Small Cell Lung Cancer
Shots:
- The approval was based on the P-III (POSEIDON) trial evaluating Imfinzi + Imjudo and CT vs CT alone in 1013 patients with metastatic NSCLC
- The results showed that the patients treated with the combination therapy achieved a 23% reduction in risk of death, patients were alive @2yrs. (33% vs 22%), 28% reduction in risk of disease progression or death, improvement in OS (25%), patients were alive @3yrs. (25% vs 13.6%). The safety profile was consistent with the known profiles of each medicine with no new safety signals. The results were presented at ESMO 2022 & published in the Journal of Clinical Oncology
- Based on the (POSEIDON) trial results, the regulatory application is currently under review in the EU, Japan & multiple other countries
Ref: AstraZeneca | Image: AstraZeneca
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
